Myeloproliferative disorder management
Ongoing care for conditions where the bone marrow makes too many blood cells, aiming mainly to lower the risk of blood clots and ease symptoms.
✓ Medically reviewed by a GMC-registered consultant · last reviewed September 2026 · next review September 2027 · how we review
In short
- MPNs are long-term conditions where the marrow makes too many blood cells; the main treatment aim is usually to lower the risk of blood clots.
- For polycythaemia vera and essential thrombocythaemia, treatment manages risk rather than curing the condition, and many people live a normal or near-normal life.
- Treatment is tailored to your type, age, symptoms and clot risk, and may include low-dose aspirin, venesection or medicines that lower blood counts.
- It involves long-term blood tests and reviews, and some MPNs can change over time, so ongoing specialist care matters.
A plain-English summary. The detail — including risks and recovery — is below.
At a glance
A general guide. Your specialist will give you advice for your situation.
Lowers the risk of blood clots, such as stroke, heart attack or clots in the legs or lungs
Treating a raised red cell count as polycythaemia vera before other causes (such as low oxygen, smoking or dehydration) have been excluded.
Blood tests check your counts are moving towards target and that medicines are tolerated. Aspirin and venesection take effect quickly; cytoreductive...
Regular blood tests and reviews with a named haematology team.
Blood tests check your counts are moving towards target and that medicines are tolerated. Aspirin and venesection...
Doses are adjusted to control counts and symptoms while keeping side effects manageable. Hydroxycarbamide can take...
Regular blood tests and reviews continue long term, with the interval depending on how stable you are. Symptoms...
If counts become harder to control, symptoms change, or blood tests suggest the condition is evolving, treatment...
What it is
Myeloproliferative neoplasms (MPNs) are a group of conditions where the bone marrow makes too many of one or more types of blood cell. The main ones are polycythaemia vera (too many red cells), essential thrombocythaemia (too many platelets) and myelofibrosis (scarring of the marrow). They are sometimes called myeloproliferative disorders.
These are long-term conditions rather than something cured by a single operation. Many are linked to a change in a gene (such as JAK2) found on a blood test. They tend to develop slowly, and some people have few or no symptoms when diagnosed.
The main reason for treatment is to lower the risk of blood clots, which can cause problems such as stroke or heart attack, and to control symptoms and the blood counts. In polycythaemia vera and essential thrombocythaemia the aim is usually to manage risk well so people can live a normal or near-normal life, rather than to cure the condition. Myelofibrosis behaves differently and may need different treatment.
Management is led by a haematologist and tailored to your type of MPN, your age, your symptoms and your clot risk. It usually involves regular blood tests and reviews over many years.
Types, options & approaches
There may be different ways to do this. The right approach depends on the clinical question and your circumstances.
Common treatment approaches in PV and ET
| Approach | Mainly used for | What it aims to do |
|---|---|---|
| Low-dose aspirin | PV and many with ET | Lower the risk of clots |
| Venesection | Polycythaemia vera | Reduce a high red cell level |
| Hydroxycarbamide | Higher-risk PV and ET | Lower blood cell production |
| Interferon | Selected/younger patients, pregnancy | Lower blood counts without chemotherapy tablets |
Treatment is chosen by your haematologist based on your type of MPN, age, symptoms and clot risk. People often have more than one of these together.
Preparing for your treatment
- Make sure you understand which MPN you have, because polycythaemia vera, essential thrombocythaemia and myelofibrosis are managed differently.
- Ask what your main clot-risk factors are and how treatment is meant to lower them.
- Tell your team about previous clots or bleeding, heart problems, and all your medicines, including anything for blood thinning.
- Mention smoking, as it adds to clot risk, and ask for support to stop if you smoke.
- If you are planning a pregnancy or could become pregnant, raise this early, as some treatments are not suitable and specialist input is needed.
- Expect regular blood tests; ask how often you will be monitored and what the targets are.
- Ask whether your raised counts have been confirmed as an MPN, or whether other causes are still being checked.
What happens
Management is led by a haematologist and based on your type of MPN and your clot risk. You will usually have regular blood tests to track your counts, and reviews to check symptoms and adjust treatment.
Many people take low-dose aspirin to lower clot risk. In polycythaemia vera, venesection is often used to bring down a high red cell level — a needle is placed in a vein and a measured amount of blood is removed over about 15 to 30 minutes, similar to giving blood, though this blood cannot be used for donation.
If clot risk is higher, counts are hard to control, or symptoms are troublesome, a medicine such as hydroxycarbamide or interferon may be added to lower the number of cells the marrow makes. These need regular blood monitoring to keep the dose safe.
Over time your team watches not just the blood counts but also your symptoms and general health, because some MPNs can change over the years. Treatment is adjusted as needed, and you should have a clear plan and contact route between appointments.
Is this treatment right for me?
A good consultation should explore whether it's the right choice for you now — including reasons to wait or consider something else.
May not be suitable if…
- Treating a raised red cell count as polycythaemia vera before other causes (such as low oxygen, smoking or dehydration) have been excluded.
- Aspirin where there is a bleeding problem or another reason it is unsafe.
- Hydroxycarbamide in pregnancy, or where blood counts are already low, without specialist review.
- Intensive treatment in someone whose clot risk is low and who would gain little, when monitoring may be enough.
- Managing an evolving MPN, such as suspected leukaemia change, outside a specialist haematology service.
Delay or rearrange if…
- The diagnosis is not yet confirmed and other causes of high counts are still being checked.
- You have an active infection or are acutely unwell.
- You are pregnant or planning pregnancy and treatment needs specialist review first.
- Blood counts are unstable and need rechecking before changing treatment.
- Key results, such as genetic testing, are still awaited.
Alternatives to discuss
- Active monitoring with aspirin alone in lower-risk essential thrombocythaemia, if appropriate.
- Venesection rather than medicines in some people with polycythaemia vera.
- Interferon instead of hydroxycarbamide in selected people, including some who are younger or pregnant.
- Targeted treatment such as ruxolitinib when standard treatment is unsuitable or stops working.
- Focusing on the underlying cause if the high count is not actually an MPN.
Before you decide
Use this as a shared-decision checklist. The aim is not just “can this be done?”, but whether it is right for you, now, with the risks and alternatives clearly understood.
What matters most to me?
Think about symptoms, daily life, work, caring responsibilities, sport, fertility, travel, appearance and anxiety — the right choice depends on your priorities, not just the medical facts.
What are all my options?
Ask about waiting, monitoring, medicines, rehabilitation, a smaller or larger procedure, a different test, NHS referral, or a second opinion where that would help.
What would make me pause?
Active infection, pregnancy, unstable medical problems, smoking, medicines that increase bleeding, poor support at home, or feeling pressured are all reasons to slow down and get tailored advice.
What happens if I do nothing today?
For some problems, waiting is safe; for others, delay can make treatment harder. A good consultation should explain the trade-off in plain English.
Benefits
- Lowers the risk of blood clots, such as stroke, heart attack or clots in the legs or lungs
- Helps control symptoms such as headaches, itching, tiredness or burning in the hands and feet
- Brings high blood counts down to safer levels
- Allows many people to live a normal or near-normal life with monitoring
- Can be adjusted over time as the condition or your needs change
Risks & complications
- Side effects from medicines, such as nausea, mouth ulcers or skin changes with hydroxycarbamide
- Bruising or feeling faint after venesection, and lower iron over time with repeated venesection
- Stomach irritation or a small increase in bleeding risk from aspirin
- Flu-like symptoms with interferon injections
- The inconvenience of regular blood tests and reviews
- Blood counts dropping too low on cytoreductive medicines, needing dose changes
- Skin sensitivity to the sun, and a need to check the skin, with long-term hydroxycarbamide
- Mood changes with interferon
- Bleeding problems, particularly when platelet counts are very high in ET
- A serious clot despite treatment, such as a stroke, heart attack or clot in the lungs
- Serious bleeding
- Over time, some MPNs can change into myelofibrosis or, less often, acute leukaemia
- Skin cancers with very long-term hydroxycarbamide, which is why skin checks and sun protection are advised
The biggest risk these conditions carry is a blood clot, which is why treatment focuses on lowering that risk. In essential thrombocythaemia, very high platelet counts can also increase bleeding risk. A small number of people see their MPN change over many years into myelofibrosis or, less often, acute leukaemia, so ongoing specialist monitoring matters. Ask your haematologist what your personal clot risk is and how your treatment and lifestyle can reduce it.
Published figures to discuss
Clot and bleeding risk in MPNs depends strongly on your age, your history of previous clots, your counts and other risk factors, so a single figure rarely fits an individual. The chance of an MPN changing into myelofibrosis or acute leukaemia is generally low but varies by the type of MPN and over time. Because robust, generalisable percentages are limited and depend so heavily on the individual, this guide avoids quoting exact rates; ask your haematologist for an estimate based on your own risk profile.
| Figure | Reported range | How to interpret it | Source / confidence |
|---|---|---|---|
| Blood clot | Key risk in PV and essential thrombocythaemia | Age, clot history, JAK2 status and blood-count control influence thrombosis risk. | NHS — Erythrocytosis (raised red cell count)nhs.ukSource-linked context |
| Bleeding despite high platelets | Recognised at very high platelet counts or acquired von Willebrand disease | High counts do not always mean clotting only; bleeding history matters. | NHS — Erythrocytosis (raised red cell count)nhs.ukSource-linked context |
| Progression to myelofibrosis or acute leukaemia | Condition- and duration-dependent | Risk varies substantially by subtype and genetics, so regular haematology follow-up is needed. | NHS — Erythrocytosis (raised red cell count)nhs.ukSource-linked context |
| Treatment side effects | Drug-specific | Venesection, aspirin, hydroxycarbamide, interferon and JAK inhibitors have different monitoring needs. | Guide sourcesClinical context |
These are literature figures, not a personalised prediction. Your own risks and likely benefits depend on your circumstances, your health, and how your care is carried out and followed up.
What happens afterwards
Managing an MPN is an ongoing process rather than something you recover from. Most people carry on with normal daily life, with treatment and regular blood tests fitted around it. 'Afterwards' here means how the condition and treatment are monitored over the long term.
- Carrying on with normal daily life around treatment and monitoring
- Some side effects from medicines that settle or are managed with dose changes
- Feeling faint or tired for a short time after venesection
- Symptoms such as itching or tiredness easing as counts come under control
- Needing regular blood tests as a routine part of life
Aftercare
- Take medicines such as aspirin or hydroxycarbamide exactly as prescribed and do not stop without advice.
- Attend all blood tests and reviews so counts and side effects are monitored.
- Protect your skin from the sun and check it regularly if you take long-term hydroxycarbamide.
- Stay well hydrated, especially around venesection, and keep active where you can to help lower clot risk.
- Do not smoke, as it adds to clot risk; ask for support to stop.
- Tell any other healthcare professional, including before surgery or dental work, that you have an MPN.
- Report new symptoms of a clot or bleeding straight away.
- Ask about pregnancy planning in advance if relevant, as treatment may need to change.
- Knowing exactly which MPN you have and your main clot-risk factors
- A clear medicine list and instructions, including aspirin if prescribed
- A blood-test and review schedule with your haematology team
- Knowing the warning signs of a clot and of bleeding
- Sun protection and skin checks planned if on long-term hydroxycarbamide
- Support to stop smoking if needed
- A contact route for urgent concerns between appointments
⚠ Get urgent help if…
- Sudden weakness or numbness on one side, face drooping, or trouble speaking — call 999, as this could be a stroke
- Sudden chest pain, severe breathlessness, or coughing up blood — call 999, as this could be a clot
- Pain, swelling, redness or warmth in a leg (possible deep vein clot)
- Unusual or heavy bleeding, or lots of new bruising
- Severe headache, visual disturbance or confusion
- Signs of infection, especially a high temperature, if you are on cytoreductive medicine
- New skin lesions or changing moles if you take long-term hydroxycarbamide
Who to contact: your clinician, clinic or test provider first (keep their number to hand). For urgent advice when you can't reach them, call NHS 111. In an emergency, call 999.
General guidance — it doesn't replace the specific advice your specialist gives you.
Results & realistic expectations
A good result in conditions such as polycythaemia vera and essential thrombocythaemia means your blood counts are controlled, your symptoms are eased, and your risk of a clot is kept as low as possible — allowing many people to live a normal or near-normal life. It does not usually mean the condition has gone, because these are long-term conditions that are managed rather than cured.
How well treatment works is judged over months and years using blood tests, your symptoms and whether you avoid clots, rather than from a single result. Be cautious about figures you read online, as outcomes vary by the type of MPN, your age and your risk factors. Ask your haematologist what 'well controlled' looks like for you.
Many people with polycythaemia vera or essential thrombocythaemia live for many years with good management, and life can be close to normal when clot risk is well controlled. However, these are lifelong conditions needing ongoing treatment and monitoring. A minority change over time into myelofibrosis or, less often, acute leukaemia, which is part of why long-term specialist follow-up is important. Your team can discuss what is realistic for your specific situation.
Related tests, treatments or support
Management often combines more than one approach, such as aspirin together with venesection or a cytoreductive medicine. Good control of other clot-risk factors — blood pressure, cholesterol, weight, activity and not smoking — is an important part of the overall plan. If an MPN changes over time, treatment may shift towards approaches used for myelofibrosis or other conditions.
Follow-up & long-term care
Follow-up is long term, with regular blood tests and clinic reviews to monitor counts, symptoms and side effects. The interval depends on how stable you are. Your team also watches for any sign the condition is changing and reviews your clot-risk factors. You should have a clear route to contact them between appointments and to seek urgent help for clot or bleeding symptoms.
- Long-term blood tests to monitor counts and the effect of treatment
- Regular reviews of symptoms, clot-risk factors and medicine side effects
- Skin checks and sun protection for those on long-term hydroxycarbamide
- Iron monitoring if you have frequent venesection
- Watching over time for any change in the condition, such as towards myelofibrosis or leukaemia
Repeat, follow-on and what comes next
- Treatment is often adjusted over time as counts, symptoms or risk change.
- If one medicine is not tolerated or stops controlling counts, another may be tried.
- Some people move from venesection alone to adding a cytoreductive medicine as risk changes.
- If the condition evolves, treatment may shift towards approaches used for myelofibrosis or other conditions.
Ask what happens if the result is unclear or needs repeating, and what is included if further tests or follow-up are needed.
What good aftercare looks like
- Regular blood tests and reviews with a named haematology team.
- Clear, written warning signs for clots and bleeding, and a route to urgent help.
- Skin checks and sun-protection advice for anyone on long-term hydroxycarbamide.
- Support to manage other clot-risk factors, including stopping smoking.
- Coordination between private and NHS care for long-term monitoring and any change in the condition.
What affects the cost
Costs vary a great deal between people and providers, and we don't publish prices. What matters is understanding what drives the cost and making sure your quote is complete. The main things that affect it:
- Consultant haematologist time for diagnosis and ongoing reviews
- The medicines used and how long they are taken
- Venesection sessions and the nursing time involved
- Regular blood tests and any genetic (such as JAK2) or marrow testing
- Monitoring for side effects, including skin checks on long-term hydroxycarbamide
- Any scans or extra tests if the condition changes
- Coordination with NHS services for long-term monitoring
- The consultant haematologist fee and who leads your long-term care
- The cost and frequency of monitoring blood tests
- Venesection sessions and facility or nursing fees
- Medicine costs and how long treatment is expected to continue
- Any genetic or bone marrow testing involved
- How reviews and dose changes are charged over time
- How private and NHS monitoring are coordinated, especially long term
On the NHS? Myeloproliferative conditions are usually managed on the NHS by a haematologist; private care is used mainly for speed of access, choice of consultant or a second opinion, often alongside NHS monitoring.
You're entitled to your total cost in writing — including reports, follow-up and what happens if the result is inconclusive — before you decide.
Consent traps and marketing red flags
These are not small details. They are often where patients lose choice, time to reflect, or realistic expectations.
Consent traps
- Not confirming the diagnosis, or not excluding other causes of a high count, before long-term treatment.
- Hydroxycarbamide started without explaining sun protection, skin checks and the need for monitoring.
- Aspirin given without weighing bleeding risk.
- Long-term outlook, including the small chance of the condition changing, not discussed honestly.
- Pregnancy plans not asked about before prescribing treatment that is unsuitable in pregnancy.
Marketing red flags
- Any claim to cure a myeloproliferative neoplasm, which is not realistic for conditions such as PV and ET.
- Offering venesection or 'blood thinning' privately without proper diagnosis and monitoring.
- Downplaying the need for long-term blood tests and specialist follow-up.
- Selling unproven supplements as a way to control or reverse an MPN.
- No clear plan for monitoring side effects or for coordinating with the NHS.
Choosing a specialist safely
- Check the specialist is on the GMC Specialist Register for this area.
- Make sure they work at a CQC-registered service, and look for membership of the relevant Royal College or professional body.
- You're entitled to time to consider and to have your questions answered before you agree — the specialist who looks after you should explain it, not a salesperson.
- Be wary of pressure: time-limited offers or deposits taken before you've had time to think are red flags, not bargains.
- You're entitled to your total cost in writing — including any follow-up — before you decide.
Questions to ask your medical professional
Take this to your consultation. A good specialist will welcome every one of these.
- Exactly which myeloproliferative condition do I have, and how does that affect my treatment?
- What is my personal risk of a blood clot, and how will treatment lower it?
- Which treatments do you recommend for me, and what are their side effects?
- What blood-count targets are we aiming for, and how often will I be monitored?
- What are the signs that the condition might be changing over time?
- How should I manage other clot-risk factors such as blood pressure and smoking?
- If I might want to get pregnant, how would that change my treatment?
- Are you on the GMC Specialist Register for this area, and which Royal College or professional body are you a member of?
- Will you be the specialist who carries out my treatment, and who looks after me afterwards?
- What are the risks for someone like me, and how often do your own patients have a problem or need it repeated or redone?
- What does a realistic result look like — and what can this treatment not achieve?
- What are my options, including waiting, doing nothing for now, or choosing a different approach?
- Can I have written information, results and aftercare instructions in a format I can use, including any accessibility or communication support I need?
- What is the total cost in writing, including any follow-ups, and how much time do I have to decide?
Frequently asked questions
Can a myeloproliferative disorder be cured?
Why do I need treatment if I feel well?
What is venesection like?
Is hydroxycarbamide chemotherapy?
Can I manage this on the NHS, or do I need to go private?
Will it turn into leukaemia?
Can I get pregnant with an MPN?
Find a verified specialist for myeloproliferative disorder management
Every consultant is GMC-checked and independently reviewed. Search by postcode and distance, or switch to a map. Ordered by rating, relevance and recency — never by who pays.
No verified consultants list this procedure yet — browse the full directory.
How we made this page
Medically reviewed by a GMC-registered consultant. Written in plain English, checked against NHS, NICE, GMC and relevant Royal College / specialist-society guidance, and kept under review. No clinic paid to appear on this page, and we publish no pricing. This is general information to help you prepare — it is not a substitute for advice from your own clinician. How we review our guides →
Source hierarchy: UK regulator and NHS/NICE guidance first, then relevant Royal College or specialist-society guidance, then peer-reviewed evidence for procedure-specific figures where available.
Sources & standards: Blood Cancer UK — Polycythaemia vera Blood Cancer UK — Essential thrombocythaemia Macmillan — Polycythaemia vera NHS — Erythrocytosis (raised red cell count) NICE TA921 — Ruxolitinib for polycythaemia vera British Society for Haematology — Guidelines
Reviews reflect patients' experience of care, not clinical outcomes. For procedure volumes and outcome data see PHIN.
Last medically reviewed 2026-09-21. Spotted something wrong or out of date? Report an error in this guide.
Related guides: Raised or abnormal blood count investigation · Chemotherapy · Targeted and immunotherapy treatment · Blood transfusion · Anaemia investigation and management